The impact of urate-lowering therapy on kidney function (IMPULsKF)
Keywords:urate-lowering therapy, kidney function, hyperuicemia, chronic kidney disease, gout
AbstractThe concept of trial launched in Ukraine in 2017 with POEM design and 36-months duration is presented. It aims to investigate the impact of two target levels of urate-lowering therapy caused by hyperuricemia on kidney function and chronic kidney disease (CKD) progression measured by estimated glomerular filtration rate and albuminuria in 180 patients with gout (n = 90) and with CKD (n = 90). The main current tasks include: 1) evaluation of serum urate acid (SUA) level most potential preserving kidney function; 2) the new onset of gout attacks depending on SUA level, both in gout and CKD objects; 3) safety and side effects of target and ultra-low SUA levels for evidence-based urate-lowering therapy optimal regime in CKD and non-CKD with gout.
Richette P, Doherty M, Pascual E, et al 2016 updated EULAR evidence-based recommendations for the management of gout Annals of the Rheumatic Diseases. BMJ. Published Online First: 25 July 2016. doi: 10.1136/annrheumdis-2016-209707.
How to Cite
Copyright (c) 2017 D.D. Ivanov
This work is licensed under a Creative Commons Attribution 4.0 International License.